The continuity of medicine supply post-Brexit

Our contingency planning team has been working hard to ensure that disruption is limited to the supply of medicines and medical products, due to the outcome of the recent Brexit trade agreements and new custom requirements for the UK.

We have been preparing for this for a number of months and all the necessary arrangements have been made to comply with the government’s new regulatory regimes.

As part of McKesson UK’s preparations, we continue to follow advice from the DHSC regarding a multi-layered approach to Brexit contingency planning. This includes our ability to deal with major disruption in the road network based on a hierarchy of responses, which includes redistributing our vehicles and drawing on our additional fleet as well as re-allocating deliveries according to the priority of the product.

We have a cross-functional team in place whose role is to continually monitor the external environment and ensure our contingency plans are aligned to the DHSC advice and market demands, and are therefore fit for purpose.

Our efforts remain focused on working to deliver a safe and prompt service in which patients receive the right medicines, in the right place, at the right time, and we will continue to work closely with the DHSC in finding solutions that do not negatively impact on patients.

We will be providing updates to our customers as necessary via direct communications and on the websites below:

For AAH updates please visit – https://www.aah.co.uk/s/brexit